NASDAQ$CCCC
C4 Therapeutics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2022 and recent business highlights.
C4 Therapeutics reported a revenue of $13.8 million for the second quarter of 2022, compared to $9.8 million for the second quarter of 2021. Net loss for the quarter was $27.4 million, or $0.56 per share, compared to a net loss of $22.6 million, or $0.51 per share, for the second quarter of 2021. Cash, cash equivalents and marketable securities totaled $397.8 million as of June 30, 2022.
- Advanced Enrollment in Phase 1/2 Clinical Trial of CFT7455
- Dosed First Patient in Phase 1/2 Clinical Trial of CFT8634
- Appointed Dr. Laura Bessen and Dr. Donna Grogan to Board of Directors
- Cash, Cash Equivalents and Marketable Securities Total $397.8 million as of June 30, 2022; Expected to Provide Runway to End of 2024
Headline financials
Revenue & EPS history
C4 Therapeutics · Revenue · Quarterly
$13.8M
Revenue by segment
C4 Therapeutics · $13.8M total across 1 segment · Q2 2022
- Collaboration agreements$13.8M+41.1%100.0%
Forward guidance
C4T expects that its cash, cash equivalents and marketable securities as of June 30, 2022, together with future payments expected to be received under existing collaboration agreements, will be sufficient to fund planned operating expenses and capital expenditures to the end of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
+1.0%
Avg return
Earnings day
+4.1%
Avg return
5 days after
-2.2%
Avg return
30 days after
38%
9 / 24 earnings
Positive
+24.0%
Q4 2023
Best reaction
-10.0%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +13.0% | — | |
| Q4 2025 | +0.4% | +17.4% | +13.9% | |
| Q3 2025 | -2.0% | -10.0% | +8.0% | |
| Q1 2025 | -0.7% | -1.4% | +21.7% | |
| Q4 2024 | -1.9% | -10.2% | -34.0% | |
| Q3 2024 | +1.4% | +10.1% | -17.7% | |
| Q1 2024 | +0.1% | -9.1% | -31.4% | |
| Q4 2023 | +24.0% | +34.5% | +13.4% | |
| Q3 2023 | -6.0% | +21.5% | +7.4% | |
| Q2 2023 | -1.7% | -3.1% | -33.8% | |
| Q1 2023 | +4.8% | +5.6% | +8.0% | |
| Q4 2022 | -10.0% | -11.0% | -40.2% | |
| Q3 2022 | -8.1% | -6.4% | -11.8% | |
| Q2 2022 | +16.7% | +6.9% | -8.7% | |
| Q1 2022 | -8.1% | -19.3% | -24.4% | |
| Q4 2021 | +13.9% | +13.9% | +24.3% | |
| Q3 2021 | -4.6% | -7.3% | -23.6% | |
| Q2 2021 | +8.0% | +5.6% | +33.6% | |
| Q1 2020 | -0.6% | +7.4% | +20.4% | |
| Q1 2021 | -0.6% | +7.4% | +20.4% | |
| Q2 2020 | +9.6% | +7.2% | -19.8% | |
| Q3 2019 | -3.7% | +8.3% | +8.3% | |
| Q4 2019 | -3.7% | +8.3% | +8.3% | |
| Q3 2020 | -3.7% | +8.3% | +8.3% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro